Cargando…

US Food and Drug Administration Accelerated Approval Program for Nononcology Drug Indications Between 1992 and 2018

IMPORTANCE: The US Food and Drug Administration (FDA) grants accelerated approval according to surrogate measures of numerous drug indications for serious or life-threatening illnesses such as infectious diseases and cancer. Investigators, including the FDA, have evaluated the program’s regulatory a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Omae, Kenji, Onishi, Akira, Sahker, Ethan, Furukawa, Toshi A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463606/ https://www.ncbi.nlm.nih.gov/pubmed/36083581 http://dx.doi.org/10.1001/jamanetworkopen.2022.30973

Ejemplares similares

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
por: Cherla, Avi, et al.
Publicado: (2021)

Recent Trends in Medicaid Spending and Use of Drugs With US Food and Drug Administration Accelerated Approval
por: Sachs, Rachel E., et al.
Publicado: (2021)

Use of Extrapolation in New Drug Approvals by the US Food and Drug Administration
por: Feldman, Daniel, et al.
Publicado: (2022)

Analysis of Supportive Evidence for US Food and Drug Administration Approvals of Novel Drugs in 2020
por: Mitra-Majumdar, Mayookha, et al.
Publicado: (2022)

Approvals and Timing of New Formulations of Novel Drugs Approved by the US Food and Drug Administration Between 1995 and 2010 and Followed Through 2021
por: Gupta, Ravi, et al.
Publicado: (2022)

Do Value Thresholds for Oncology Drugs Differ from Nononcology Drugs?
por: Bae, Yuna Hyo Jung, et al.
Publicado: (2014)

Patient Participation in Clinical Trials of Oncology Drugs and Biologics Preceding Approval by the US Food and Drug Administration
por: Hutchinson, Nora, et al.
Publicado: (2021)

Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action
por: Olivier, Timothée, et al.
Publicado: (2021)

Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017
por: Skydel, Joshua J., et al.
Publicado: (2022)

Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration
por: Modi, Natansh D., et al.
Publicado: (2022)

Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019
por: Dhodapkar, Meera, et al.
Publicado: (2021)

Use of US Food and Drug Administration Expedited Drug Development and Review Programs by Orphan and Nonorphan Novel Drugs Approved From 2008 to 2021
por: Monge, Andrea N., et al.
Publicado: (2022)

US Food and Drug Administration Approvals of Drugs and Devices Based on Nonrandomized Clinical Trials: A Systematic Review and Meta-analysis
por: Razavi, Marianne, et al.
Publicado: (2019)

Association Between Food and Drug Administration Approval and Disparities in Immunotherapy Use Among Patients With Cancer in the US
por: Ermer, Theresa, et al.
Publicado: (2022)

Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval
por: Parikh, Ravi B., et al.
Publicado: (2023)

In Vitro‐to‐In Vivo Extrapolation of Transporter Inhibition Data for Drugs Approved by the US Food and Drug Administration in 2018
por: Yu, Jingjing, et al.
Publicado: (2020)

Rituximab utilization for approved and off‐label nononcology indications and patients’ experiences with the Patient Alert Card
por: Sarsour, Khaled, et al.
Publicado: (2020)

Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017
por: Zhang, Audrey D., et al.
Publicado: (2020)

Therapeutic Value of Drugs Granted Accelerated Approval or Conditional Marketing Authorization in the US and Europe From 2007 to 2021
por: Vokinger, Kerstin N., et al.
Publicado: (2022)

Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments
por: Skydel, Joshua J., et al.
Publicado: (2019)

Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016
por: Ladanie, Aviv, et al.
Publicado: (2020)

Quantification of US Food and Drug Administration Premarket Approval Statements for High-Risk Medical Devices With Pediatric Age Indications
por: Lee, Samuel J., et al.
Publicado: (2021)

Comparison of Amitriptyline and US Food and Drug Administration–Approved Treatments for Fibromyalgia: A Systematic Review and Network Meta-analysis
por: Farag, Hussein M., et al.
Publicado: (2022)

Risk of Recall Associated With Modifications to High-risk Medical Devices Approved Through US Food and Drug Administration Supplements
por: Dubin, Jonathan R., et al.
Publicado: (2023)

Proportion attributable to contextual effects in general medicine: a meta-epidemiological study based on Cochrane reviews
por: Tsutsumi, Yusuke, et al.
Publicado: (2023)

Comparison of Duration of Postapproval vs Pivotal Trials for Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval, 2009-2018
por: Wallach, Joshua D., et al.
Publicado: (2021)

Characteristics of Recent Generic Drug Approvals by the US Food and Drug Administration
por: Jiao, Kuo, et al.
Publicado: (2019)

Characteristics of Preapproval and Postapproval Studies of Vaccines Granted Accelerated Approval by the US Food and Drug Administration
por: Egilman, Alexander, et al.
Publicado: (2021)

National Comprehensive Cancer Network Guideline Recommendations of Cancer Drugs With Accelerated Approval
por: Cliff, Edward R. Scheffer, et al.
Publicado: (2023)

Risk of Recall Among Medical Devices Undergoing US Food and Drug Administration 510(k) Clearance and Premarket Approval, 2008-2017
por: Dubin, Jonathan R., et al.
Publicado: (2021)

Review of Evidence Supporting 2022 US Food and Drug Administration Drug Approvals
por: Kaplan, Robert M., et al.
Publicado: (2023)

Association of Research and Development Investments With Treatment Costs for New Drugs Approved From 2009 to 2018
por: Wouters, Olivier J., et al.
Publicado: (2022)

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2020
por: Kayki-Mutlu, Gizem, et al.
Publicado: (2021)

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021
por: Kayki-Mutlu, Gizem, et al.
Publicado: (2022)

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022
por: Kayki-Mutlu, Gizem, et al.
Publicado: (2023)

Spending on Phased Clinical Development of Approved Drugs by the US National Institutes of Health Compared With Industry
por: Zhou, Edward W., et al.
Publicado: (2023)

The role of antiresorptive drugs and medication-related osteonecrosis of the jaw in nononcologic immunosuppressed patients: A systematic review
por: Sacco, Roberto, et al.
Publicado: (2021)

Time for the US food and drug administration approval of condoms for anal intercourse
por: Nguyen, Brian T., et al.
Publicado: (2019)

Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor–T Cell Therapy for Hematological Malignant Neoplasms
por: Al Hadidi, Samer, et al.
Publicado: (2022)

Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals
por: Lammers, Austin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_fkts6fvmlb9p09m72tq0qial97